Stocks Health care TARS

NASDAQ · Health care

Tarsus Pharmaceuticals, Inc. (TARS)

Tarsus Pharmaceuticals, Inc. brought in $682.2M of revenue over the twelve months to September 30, 2026, up 86.3% from a year earlier. It posted a net loss of $702.2M. In fiscal 2025 capital spending exceeded operating cash flow by $22.3M. At September 30, 2026 it held $136.5M in cash against $72.9M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.

Watch TARS in 60 seconds

Follow TARS

Free, no password. An email when TARS files with the SEC.

Key facts about Tarsus Pharmaceuticals, Inc.

Net worth

Tarsus Pharmaceuticals, Inc. has a market value (market cap) of $3.2B at the latest share price, and shareholders' equity of $104M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Revenue and profit

In fiscal 2025 revenue was $451.4M (+146.7% year on year), with a net loss of $66.4M. Over the 12 months to September 30, 2026: revenue $682.2M, net loss $702.2M.

Cash flow

In fiscal 2025 operations used $12.5M of cash.

Latest report

The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR

Next earnings report

Tarsus Pharmaceuticals, Inc.'s next report is expected around February 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

What Tarsus Pharmaceuticals, Inc. does

Tarsus Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TARS.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Earnings: every quarter and the next report date

Full financial statements: income, balance sheet and cash flow

Where TARS ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Tarsus Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. November 5, 2026
   Passive stake (5% or more) SCHEDULE 13G
2. November 3, 2026
   Quarterly report 10-Q · period to September 30, 2026Revenue rose 64% to $194.6M versus the same quarter last year; diluted EPS -$14.40 versus -$0.30.
3. November 3, 2026
   Quarterly results 8-K
4. October 13, 2026
   Shelf registration to sell securities S-3ASR
5. October 13, 2026
   Shelf registration to sell securities S-3ASR
6. October 13, 2026
   Exhibits 8-K/A
7. September 10, 2026
   Acquisition or sale completed 8-K
8. August 13, 2026
   Passive stake changed SCHEDULE 13G/A
9. August 6, 2026
   Quarterly report 10-Q · period to June 30, 2026Revenue rose 69% to $173.9M versus the same quarter last year; diluted EPS -$0.43 versus -$0.48.
10. August 6, 2026
    Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on November 5, 2026. Insider transactions on SEC

Insider trades

What the people running Tarsus Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

Insiders sold $5.2M worth of shares in the last 90 days and bought none on the open market. All of the selling was pre-planned under Rule 10b5-1 trading plans.

All insider filings on SEC.gov · Where insiders are buying across the market

Who owns TARS

Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.

5% holders

Anyone who owns more than 5% of a class of shares must say so on Schedule 13D (if they may seek to influence the company) or 13G (a passive holder). The latest filing of each holder is shown: 13G filings of the last 2 years, 13D of the last 3.

Latest filings below 5%: Jennison Associates LLC 4% (May 6, 2026); The Vanguard Group 0% (March 27, 2026); Tang Capital Management, LLC 2.8% (February 17, 2026); Cowen Financial Products LLC 4.9% (February 13, 2025); Cormorant Asset Management, LP 1.31% (November 14, 2024).

Largest institutional holders

Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 257 managers reported a position.

Insiders

Reported holdings of insiders who filed a Form 4 in the last 12 months: the shares each one held after their latest reported transaction. This is not the total held by all insiders.

14 insiders reported holding 1,325,404 shares in total, about $97.6M at the last price.

Schedule 13D/13G filings on SEC.gov

All filings on SEC EDGAR

Questions about TARS

What does Tarsus Pharmaceuticals, Inc. do?

Tarsus Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as TARS. Its shares trade on NASDAQ under the ticker TARS.

What is Tarsus Pharmaceuticals, Inc.'s net worth?

Tarsus Pharmaceuticals, Inc. has a market value (market cap) of $3.2B at the latest share price, and shareholders' equity of $104M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.

Is Tarsus Pharmaceuticals, Inc. profitable?

No. Over the twelve months to September 30, 2026 it reported a net loss of $702.2M on revenue of $682.2M.

How much revenue does Tarsus Pharmaceuticals, Inc. make?

Over the twelve months to September 30, 2026 Tarsus Pharmaceuticals, Inc. reported revenue of $682.2M. That is 86.3% more than a year earlier.

When did Tarsus Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 5, 2026.

When is Tarsus Pharmaceuticals, Inc.'s next earnings report?

Tarsus Pharmaceuticals, Inc.'s next report is expected around February 22, 2027. That is an estimate from its filing rhythm, not a date the company has announced.

Similar companies

Compare TARS with

Compare TARS with any company

Follow TARS

Get an email when Tarsus Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow TARS

Free, no password. An email when TARS files with the SEC.

Where the numbers come from

Financial figures are the values Tarsus Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.